



Fax completed form to: (855) 840-1678  
 If this is an URGENT request, please call (800) 882-4462  
 (800.88.CIGNA)

# Symdeko (tezacaftor/ivacaftor)

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:	* Date of Birth:	
Office Fax:			* Patient Street Address:		
Office Street Address:			City:	State:	Zip:
City:	State:	Zip:	Patient Phone:		

**Urgency:**

- Standard  Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)

**Medication requested:**

- Symdeko 50mg-75mg/75mg  Symdeko 100mg-150mg/150mg

Directions for use: \_\_\_\_\_ Duration of therapy: \_\_\_\_\_ ICD10: \_\_\_\_\_  
 (if more than 2 tablets per day) Please provide clinical support for requesting this dosing/quantity for your patient (examples could include past doses tried, past medications tried, pertinent patient history, etc).

Is this for a new start or continued therapy with Symdeko?  new start  continued therapy

Prior to starting the requested medication, which best described your patient?

- previously asymptomatic, or have mild clinical manifestations  
 measurable lung disease or end organ involvement  
 unknown

(if previously asymptomatic or mild manifestations) Has your patient had any clinical decline? Please provide supportive documentation.  Yes  No

(if measurable lung disease or end organ involvement) Has there been documented clinical response (for example, improvement in FEV1, reduced number of pulmonary exacerbations, improvement in body mass index [BMI] or improvement on the patient reported Cystic Fibrosis Questionnaire-Revised respiratory domain score)? Please provide supportive documentation.  Yes  No

Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient?  Yes  No

**Diagnosis related to use:**

- Cystic Fibrosis\*\*  
 cystic fibrosis transmembrane conductance regulator (CFTR)-related disorder (for example, congenital absence of the vas deferens (CAVD), isolated pancreatitis, recurrent sinusitis or bronchitis)  
 cystic fibrosis transmembrane conductance regulator (CFTR)-related metabolic syndrome, CF Screen Positive, Inconclusive Diagnosis (CRMS/CFSPID)  
 Other (please specify)

\*\*submit clinical notes and lab results confirming the standard CF diagnostic criteria

**Clinical Information:**

**\*\*\*This drug requires supportive documentation (chart notes, lab and test results, etc). Supportive documentation for all answers must be attached with this request\*\*\***

Attach CFTR gene testing confirming the presence of any of the following mutations:

A1067T, A455E
D110E, D110H, D1152H, D1270N, D579G
E193K, E56K, E831X

F1052V, F1074L, F508del
K1060T, L206W, P67L
R1070W, R117C, R347H, R352Q, R74W
S945L, S977F
711+3A→G, 2789+5G→A, 3272-26A→G, 3849+10kbC→T

Is there documentation that your patient has two copies of the F508del mutation (homozygous) in the CFTR gene?  Yes  No  
 (if no) Is there documentation that your patient has at least ONE mutation that is responsive to tezacaftor/ivacaftor (Symdeko) as specified in the FDA product label: A1067T, A455E, D110E, D110H, D1152H, D1270N, D579G, E193K, E56K, E831X, F1052V, F1074L, K1060T, L206W, P67L, R1070W, R117C, R347H, R352Q, R74W, S945L, S977F, 711+3A->G, 2789+5G->A, 3272-26A->G, 3849+10kbC->T mutation?  Yes  No

Will the requested drug be used in combination therapy with Kalydeco (ivacaftor), Orkambi (lumacaftor/ivacaftor), or Trikafta (elexacaftor/tezacaftor/ivacaftor)?  Yes  No

**Additional pertinent information:** *(please include clinical reasons for drug, relevant lab values, etc.)*

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

**Prescriber Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**Save Time! Submit Online at:** [www.covermymeds.com/main/prior-authorization-forms/cigna/](http://www.covermymeds.com/main/prior-authorization-forms/cigna/) or via SureScripts in your EHR.

*Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at [cigna.com](http://cigna.com).*

v100120

“Cigna” is a registered service mark, and the “Tree of Life” logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005